Sharescart Research Club logo
Products
Research
Tools
About
  • Home
  • /
  • Dr Reddys Lab
Join Channel

Dr. Reddy's Lab

₹1235.6 18.4 | 1.5%

Last updated: 15:57

Consolidated Standalone

Last updated: 15:57

Dr. Reddy's Lab Overview

Dr. Reddy's Laboratories Limited is an India-based pharmaceutical corporation. The Company's segments consist of Global Generics, which is engaged in production and marketing prescription and over the counter finished pharmaceutical merchandise ready for consumption by patient, marketed under a brand name (branded formulations) or as usual finished dosages with healing equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and advertising and marketing active phar...Read More

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Dr. Reddy's Lab Key Financials

Market Cap ₹103127 Cr.

Stock P/E 18

P/B 2.8

Current Price ₹1235.6

Book Value ₹ 445.7

Face Value 1

52W High ₹1378

Dividend Yield 0.65%

52W Low ₹ 1025.9

Edit Ratio

Dr. Reddy's Lab Share Price

₹ | |

Volume
Price

Dr. Reddy's Lab Quarterly Price

Quarterly Monthly
Show Value Show %

Dr. Reddy's Lab Peer Comparison

Dr. Reddy's Lab Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 6903 7237 7114 7696 8038 8381 8528 8572 8828 8753
Other Income 315 216 198 187 308 150 522 290 324 269
Total Income 7218 7453 7311 7883 8346 8531 9051 8862 9152 9022
Total Expenditure 4894 5214 5283 5566 5962 6108 6531 6399 6818 6866
Operating Profit 2323 2239 2029 2317 2384 2423 2520 2464 2334 2156
Interest 35 39 59 60 76 82 66 83 91 94
Depreciation 376 374 368 381 397 471 455 476 505 521
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 1913 1826 1602 1877 1911 1870 2000 1905 1739 1541
Provision for Tax 435 448 295 490 576 470 419 495 408 354
Profit After Tax 1478 1378 1306 1387 1336 1400 1581 1410 1331 1187
Adjustments 4 3 4 6 -80 14 12 8 17 23
Profit After Adjustments 1482 1381 1310 1392 1256 1414 1593 1418 1347 1210
Adjusted Earnings Per Share 17.8 16.6 15.7 16.7 15.1 17 19.1 17 16.1 14.5

Dr. Reddy's Lab Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 15023 15568 14196 14281 15448 17517 19048 21545 24670 28011 32644 34681
Other Income 275 295 172 155 338 621 291 485 1056 894 1097 1405
Total Income 15298 15863 14368 14436 15786 18138 19339 22030 25725 28905 33741 36087
Total Expenditure 11530 11983 11724 11930 12270 15047 15178 17778 18321 20078 24097 26614
Operating Profit 3769 3880 2644 2506 3516 3091 4161 4252 7405 8827 9644 9474
Interest 109 83 63 79 89 98 97 96 143 171 283 334
Depreciation 760 939 1027 1077 1135 1163 1229 1165 1250 1470 1704 1957
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 2900 2859 1554 1350 2336 1886 2884 3061 6049 7201 7680 7185
Provision for Tax 563 751 297 438 386 -140 932 879 1541 1623 1954 1676
Profit After Tax 2336 2108 1257 912 1950 2026 1952 2183 4507 5578 5725 5509
Adjustments 0 23 35 34 0 0 0 0 0 0 -70 60
Profit After Adjustments 2336 2131 1292 947 1950 2026 1952 2183 4507 5578 5655 5568
Adjusted Earnings Per Share 27.4 25 15.6 11.4 23.5 24.4 23.5 26.2 54.1 66.9 67.8 66.7

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 17% 15% 13% 8%
Operating Profit CAGR 9% 31% 26% 10%
PAT CAGR 3% 38% 23% 9%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -4% 13% 4% 8%
ROE Average 19% 21% 17% 16%
ROCE Average 23% 25% 21% 17%

Dr. Reddy's Lab Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 9853 12570 12262 12572 14024 15599 17642 19212 23286 28255 33550
Minority's Interest 0 0 0 0 0 0 0 0 0 0 378
Borrowings 1432 1069 545 2509 2200 130 630 575 128 599 786
Other Non-Current Liabilities 247 -192 -89 30 -87 -938 -827 -1083 -406 -636 -154
Total Current Liabilities 6821 6347 8420 6894 5897 7214 8104 9766 8572 9588 13034
Total Liabilities 18353 19794 21138 22004 22034 22005 25548 28470 31580 37806 47594
Fixed Assets 5377 6563 6931 6968 7191 6850 8206 8122 9219 10426 18226
Other Non-Current Assets 1099 1437 4524 4537 3733 2556 2792 2561 1935 2575 4350
Total Current Assets 11877 11794 9684 10498 11110 12599 14535 17788 20425 24805 25018
Total Assets 18353 19794 21138 22004 22034 22005 25548 28470 31580 37806 47594

Dr. Reddy's Lab Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 862 540 492 378 254 223 196 1482 1485 578 711
Cash Flow from Operating Activities 2524 3263 2144 1803 2870 2984 3570 2811 5888 4543 4643
Cash Flow from Investing Activities -2265 -2039 -1840 -1488 -773 -492 -2266 -2639 -4137 -4028 -5808
Cash Flow from Financing Activities -433 -1700 -369 -444 -2133 -2516 -30 -242 -2686 -376 1891
Net Cash Inflow / Outflow -174 -477 -65 -129 -35 -24 1275 -70 -936 139 726
Closing Cash & Cash Equivalent 583 492 378 254 223 196 1482 1485 578 711 1459

Dr. Reddy's Lab Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 27.42 24.98 15.59 11.41 23.49 24.38 23.46 26.23 54.11 66.88 67.81
CEPS(Rs) 36.34 35.72 27.55 23.97 37.17 38.38 38.23 40.24 69.12 84.51 89.08
DPS(Rs) 4 4 4 4 4 5 5 6 8 8 8
Book NAV/Share(Rs) 114.58 146.3 146.94 150.47 168 186.46 210.52 229.2 277.8 337.21 400.54
Core EBITDA Margin(%) 23.13 23.03 17.41 16.46 20.57 14.1 20.32 17.49 25.74 28.32 26.18
EBIT Margin(%) 19.92 18.89 11.39 10.01 15.7 11.33 15.65 14.65 25.1 26.32 24.39
Pre Tax Margin(%) 19.19 18.36 10.94 9.46 15.12 10.77 15.14 14.21 24.52 25.71 23.53
PAT Margin (%) 15.47 13.54 8.86 6.39 12.62 11.57 10.25 10.13 18.27 19.91 17.54
Cash Profit Margin (%) 20.5 19.57 16.09 13.93 19.97 18.21 16.7 15.54 23.34 25.16 22.76
ROA(%) 13.67 11.05 6.14 4.23 8.86 9.2 8.21 8.08 15.01 16.08 13.41
ROE(%) 26.63 18.95 10.2 7.4 14.75 13.76 11.82 11.93 21.36 21.76 18.61
ROCE(%) 22.7 19.55 9.77 8.21 13.66 11.12 15.49 14.59 26.22 26.86 23.25
Receivable days 89.72 96.43 101.86 100.33 94.98 93.92 95.74 98.6 103.01 99.54 95.44
Inventory Days 60.27 60.11 69.56 73.63 74.03 71.52 77.11 81.57 73.65 73.12 75.27
Payable days 84.85 86.14 96.95 108.04 109.69 95.02 100.14 99.98 108.07 108.56 96.23
PER(x) 25.43 24.3 33.78 36.51 23.62 25.57 38.5 32.83 17.08 18.41 16.87
Price/Book(x) 6.09 4.15 3.58 2.77 3.3 3.34 4.29 3.76 3.33 3.65 2.86
Dividend Yield(%) 0.57 0.66 0.76 0.96 0.72 0.8 0.55 0.7 0.87 0.65 0.7
EV/Net Sales(x) 4.12 3.51 3.39 2.76 3.22 3.07 3.99 3.37 3.11 3.68 2.99
EV/Core EBITDA(x) 16.42 14.08 18.22 15.71 14.13 17.41 18.29 17.08 10.35 11.66 10.12
Net Sales Growth(%) 11.99 3.63 -8.81 0.6 8.17 13.39 8.74 13.11 14.5 13.54 16.54
EBIT Growth(%) 7.5 -2.24 -45.02 -11.62 69.65 -18.18 50.23 5.93 96.1 19.07 8.01
PAT Growth(%) 19.01 -9.79 -40.35 -27.43 113.72 3.9 -3.67 11.83 106.52 23.75 2.64
EPS Growth(%) 18.87 -8.92 -37.6 -26.81 105.96 3.77 -3.79 11.83 106.27 23.6 1.38
Debt/Equity(x) 0.44 0.27 0.4 0.41 0.28 0.14 0.17 0.18 0.06 0.07 0.14
Current Ratio(x) 1.74 1.86 1.15 1.52 1.88 1.75 1.79 1.82 2.38 2.59 1.92
Quick Ratio(x) 1.36 1.46 0.81 1.1 1.31 1.26 1.23 1.3 1.82 1.92 1.37
Interest Cover(x) 27.58 35.61 25.51 18.14 27.27 20.18 30.73 32.96 43.36 43.09 28.15
Total Debt/Mcap(x) 0.07 0.06 0.11 0.15 0.08 0.04 0.04 0.05 0.02 0.02 0.05

Dr. Reddy's Lab Shareholding Pattern

# Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Promoter 26.66 26.65 26.65 26.65 26.64 26.64 26.64 26.64 26.64 26.64
FII 28.2 28.62 29.14 27.68 27.53 26.85 25.75 25.32 24.69 22.34
DII 21.04 18.65 18.31 20.73 21.48 22.9 25.62 26.74 27.98 30.44
Public 10.09 10.74 10.55 10.36 10.13 10.38 10.45 10.27 9.86 9.72
Others 14.02 15.33 15.35 14.59 14.22 13.23 11.54 11.04 10.83 10.87
Total 100 100 100 100 100 100 100 100 100 100

Dr. Reddy's Lab News

Dr. Reddy's Lab Pros & Cons

Pros

  • Company has delivered good profit growth of 23% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 21%
  • Debtor days have improved from 108.56 to 96.23days.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 26.64%.

* The pros and cons are machine generated.

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares
whatsapp

Please Login!

Click to Login
OR
Get free Account

Error!